Impaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia

Area of Science:

• Biochemistry
• Molecular Biology
• Physiology

Background:

• Skeletal muscle wasting is a hallmark of cancer cachexia, severely impacting patient outcomes.
• Mitochondrial dysfunction is implicated in muscle wasting, but its upstream causes in cancer are unclear.

Purpose of the Study:

• To elucidate the molecular mechanisms driving mitochondrial dysfunction in cancer-associated skeletal muscle wasting.
• To identify potential therapeutic targets for counteracting muscle wasting in cancer cachexia.

Main Methods:

• Investigated the role of cAMP-dependent protein kinase A (PKA) and CREB1 in tumor-induced muscle wasting in mice.
• Utilized pharmacological inhibition of phosphodiesterase 4 (PDE4) to restore cAMP-PKA-CREB1 signaling.
• Assessed mitochondrial gene expression, mitochondrial function, and skeletal muscle mass.

Main Results:

• Cancer suppressed cAMP-PKA-CREB1 signaling in skeletal muscle, downregulating mitochondrial integrity genes.
• Inhibition of PDE4 rescued mitochondrial gene expression and function.
• Pharmacological restoration of cAMP-PKA-CREB1 signaling mitigated skeletal muscle wasting in male mice.

Conclusions:

• Tumor-induced suppression of the cAMP-PKA-CREB1 axis is a key mechanism of mitochondrial dysfunction in cancer cachexia.
• Targeting PDE4, especially PDE4D, offers a potential therapeutic strategy to preserve muscle mitochondrial function and combat wasting.